INTRODUCTION
Renal cell carcinoma (RCC) has a well-known propensity to metastasize. Despite the fact that this tumor is being diagnosed as an incidental finding before symptoms with increasing frequency, typically, 25 %to 30 % of patients have metastases at presentation (1). Furthermore, many patients will manifest metastasis after resection of apparently localized disease, especially when the tumor is pT3 or greater. In our experience at The University of Texas M. D. Anderson Cancer Center, 68 of 286 patients (24 %) with pT1-3 tumors who underwent radical nephrectomy between 1985 and 1994 developed metastases (2). The incidence was 7%(8/113) for patients with pT1 tumors, 27 % (17/64) for pT2, and 39 % (43/109) for pT3. Similarly, Ljungberg reported that 56 of 187 patients (30 %) with pT1-3 N0 M0 tumors got metastases, with the incidence again higher in patients with higher stage tumors (3).
Thus, it can be seen that metastatic RCC is a common clinical problem. If systemic therapy were always completely successful in eradicating all disease, consideration of surgery would not be necessary. However, RCC is unresponsive to traditional chemotherapy, and only moderately responsive to immunotherapy (also called biologic therapy), which is currently considered "standard" therapy. Systemic therapy today can be expected to produce objective responses in only 15 % to 35 % of patients, fewer than one-third of which are complete regressions. Nonetheless, since many patients respond to systemic therapy with a partial regression of metastases or prolonged stabilization, surgery is often considered even though the role of surgery for advanced RCC, par-ticularly in combination with systemic therapy, is clearly not yet defined. We believe there are circumstances where surgery plays a legitimate role in the management of patients with metastatic RCC, particularly when the patient seeks an aggressive treatment option. Clinical situations in which surgery is potentially appropriate include excision of a solitary metastasis, limited multiple metastases, a residual mass after response to systemic therapy, local recurrence, and even palliation.
EXCISION OF SOLITARY METASTASIS
Metastasectomy for solitary metastasis was firmly established as potentially effective by the mid-1970s after several groups reported 5-year overall survival rates of 29 % to 35 % (1, 4, 5). Since then, many additional reports have confirmed this early experience, and the 5-year survival is still widely quoted to be about 35 %, although the actual outcome depends on multiple factors such as performance status, site of metastasis, interval after nephrectomy, and whether the metastasis is completely resected (6).
Recently, Kavolius reported on 94 patients undergoing resection of a "solitary metastasis" (which included multiple metastases in a solitary organ) as first recurrence of disease (7). Patients with completely resected solitary metastasis fared better than those who underwent complete resection of multiple metastases (n =47), with a 5-year overall survival rate of 52 % compared with 29 % (p < 0.005). Disease-free survival rate by site was 44 % for patients with a solitary metastasis in the lung, 42 % gland (any glandular organ), 20 % brain, 40 % bone, and 50 % for soft tissue metastases. Overall survival rates for these patients by site were 54 % for patients with lung metastases, 63 % gland, 18 % brain, 40 % bone, and 75 % soft tissue metastases.
van der Poel recently reported the results of 152 resections of RCC metastases in 101 patients at four Dutch hospitals (8). However, unlike the experience of Kavolius and many others, he reported no im-proved survival after resection in the 40 patients with solitary metastasis compared to patients with multiple metastases.
At The University of Texas M. D. Anderson Cancer Center, 179 (8.5 %) of 2100 patients who were known to have metastatic RCC between 1984 and 1997 underwent resection for an apparently solitary metastatic lesion (9). Sites resected included lung (50); axial bone (29); appendicular bone (27); visceral organ (23); brain (23); locoregional location, including renal fossa or regional lymph nodes (17) ; and skin (10) . The overall 5-year survival rate was 29 %. Disease-specific 5-year survival rate for all sites was 19 %, but survival rates were dependent upon the location of the metastasis: 56 % for patients with a solitary metastasis in the lung, 49 % locoregional location, 28 % skin, 20 % visceral organs, 18 % appendicular bone, 13 % brain, and 9% for axial bones. Patients who developed a metachronous solitary metastasis fared better than those with a synchronous solitary metastasis (5-year survival rates of 39 % and 22 %, respectively) regardless of the site of metastasis. Among the 40 patients with recurrent disease after resection of a lung metastasis, 24 (60 %) were able to undergo a subsequent resection compared with only 14 (25 %) of the 56 patients with recurrent bone metastasis.
Overall, patients with solitary lung and locoregional metastases had the most favorable outcome in our series, but the results support treating most patients with solitary metastasis with surgical resection. Furthermore, the published results suggest that adjuvant systemic therapy after resection of a solitary metastasis need not be given routinely, but rather only on protocol.
The case of patient J. E. S. illustrates why adjuvant systemic therapy should be given only when dictated by protocol. In September 1980, at age 56, 2 years after right radical nephrectomy for RCC, he underwent resection of a solitary metastasis in the contralateral left adrenal gland. He did not receive adjuvant therapy postoperatively. The patient did very well until 1996, when he began to complain of fatigue and left upper-quadrant pain. CT scan showed an 8-cm × 10-cm × 11-cm poorly defined mass in the region of the celiac artery. Resection of this mass along with the spleen and tail of the pancreas in September 1996 again revealed metastatic RCC. Surgical margins were negative for tumor. The patient is currently alive without clinical evidence of disease 23 and onehalf years after initial resection of a solitary adrenal metastasis, and 8 and one-half years after resection of a local recurrence in the surgical bed without ever receiving systemic therapy.
RESECTION OF MULTIPLE METASTASES
Resection of multiple metastases has been reported for many organ sites and may be worth considering in selected patients, especially if longer survival times are anticipated. A number of factors predict for a shorter disease-free interval and survival. They include high nuclear grade (especially sarcomatoid his-tology), poor performance status, synchronous metastases or short disease-free interval after nephrectomy, metastatic sites other than lung (particularly liver and brain), and multiple organ site involvement (10, 11) . The presence of one or more of these adverse prognostic indicators argues against aggressive surgical resection of metastases.
Many of the reports in the literature on resection of metastases are organized by organ site and include data on many types of malignancy. Although RCC may have unique features in terms of natural history and response to treatment, we cannot be sure that the published results of metastasectomy are all disease specific and not site specific. Certainly, the surgical considerations will be similar for a given organ site, regardless of tumor type. For this reason, some information is included from clinical experience gained in patients with tumors other than RCC.
LUNG
The most frequently diagnosed renal metastases occur in the lungs, which, because of the relative ease and safety of thoracotomy, is also the site most amenable to resection of metastases. Typically, in series that report the results of pulmonary metastasectomy for RCC and non-renal primary tumors, the size and number of lung metastases, whether they can be completely resected, and the disease-free interval are important predictors for survival.
Although preservation of adequate pulmonary function is important, the intent of surgery should be to resect all known metastases. Pastorino reported on 4572 patients who underwent complete surgical resection and compared them to 634 patients who had incomplete resections (12) . The actuarial 5-and 10-year survival rates were 36 % and 26 %, respectively, after complete resection, compared with 13 % and 7%, respectively, with incomplete resections. For patients who have recurrent disease in the lungs after metastasectomy, there appears to be a benefit to repeat resection, even more than once.
Tanguay addressed the potential benefits from combining surgery with systemic therapy in 51 patients who had 68 thoracotomies (13) . Twenty-two patients underwent initial surgical resection (20 had only one or two nodules), 16 of whom received systemic therapy following surgery. The remaining 29 patients (20 of whom had 4 or more residual nodules) underwent thoracotomy for residual disease after a partial response to systemic therapy. Median time to relapse was 6 months in patients treated with initial surgery and 8.5 months in patients treated with delayed surgery, despite the fact that the latter group of patients had substantially more disease. Of 22 patients who underwent initial surgery, 12 (55 %) were alive after median followup of 48 months, while 19 (66 %) of 29 patients who received initial systemic therapy were alive after 27 months. The authors emphasize, however, that this was not a randomized trial and these were not comparable groups: the disease burden was much greater in the group of patients who received initial systemic therapy. How-ever, the promising results seem to support initial systemic therapy for patients with greater disease burden. BONE Among patients with RCC and multiorgan metastases, 50 % will have osseous metastasis, 15 %-30 % of which will be solitary (6, 14) . The axial skeleton, thoracolumbar spine, and pelvis harbor 80 % of osseous metastases, which are typically lytic. As with lung metastases, a long disease-free interval between nephrectomy and first metastasis, and solitary metastasis versus multiple metastases correlate with longer survival (15) .
Resection of an osseous metastasis should be considered when an impending fracture appears imminent. Surgical resection of osseous metastases may pose special problems, particularly when there are axial skeletal lesions. Using contemporary techniques, however, even vertebral metastases can now be resected; adjuvant radiation therapy is commonly given after surgery. Of 33 patients with cord compression due to metastatic RCC in one series, 88 % had partial or complete relief of pain and 64 % who were bedridden were able to walk (16) .
At The University of Texas M. D. Anderson Cancer Center, 107 spinal operations were performed on 79 patients with metastatic RCC (17) . Ninety-four (88 %) had disabling pain and 55 (51 %) had neurologic dysfunction. Although the median survival was only 12.3 months, pain decreased in 89 % of patients, and neurologic function improved in 65 %, including 7 of 14 bedridden patients who were able to walk. BRAIN Renal metastases to the brain, unless solitary, are commonly associated with a poor prognosis. Nonetheless, brain metastases tend to be well-circumscribed with a surrounding pseudocapsule and can often be removed with low morbidity and mortality. Resection of a solitary brain metastasis, RCC included, frequently provides immediate and prolonged improvement in neurological symptoms. For comparable tumors, the palliative benefit of surgical resection of brain metastases appears to be considerably greater than what can be achieved using radiotherapy or dexamethasone alone (18) .
Wroń ski evaluated 50 consecutive patients with RCC brain metastases who underwent surgical resection (19) . Survival time from craniotomy was 12.6 months. Other investigators have noted similar results, although the majority of patients with multiple metastases should be considered for brain irradiation.
LIVER
Although liver resection is commonly performed for metastases due to colorectal cancer and breast cancer, the experience with liver metastasectomy in patients with RCC is more limited. Stief reported on 17 patients who underwent surgical exploration for metachronous liver metastases secondary to RCC (20) . Resection was feasible in 13 patients, but complete resection was accomplished in only 11 patients. Mean survival time was 16 months in the 13 resectable patients, but the mortality rate was 31 % (4 of 13) and there was significant morbidity in another two patients. In general, few patients with hepatic metastases have resectable disease, and the majority of patients who undergo successful liver resection for RCC develop recurrent disease in the liver or other sites.
MISCELLANEOUS SITES
Multiple papers in the literature discuss the incidence and results of surgical resection of metastases, both solitary and multiple, in a wide variety of other organs, particularly the adrenal gland, pancreas, and various head and neck sites. However, like the individual sites presented in more detail above, management of metastases in these sites should be guided by several principles. First, if the metastasis is solitary, aggressive surgical management appears to be justified by experience that now exceeds 60 years. Second, although limited metastases may in some cases behave like a solitary metastasis, a decision to operate should be guided by the organ site involved, the disease course to date, and the difficulty and morbidity of the surgery required to completely resect all known disease. Finally, for the patient who has multiple metastases, initial systemic therapy followed by surgical resection of any residual mass seems most prudent, unless the surgery is being done in an attempt to alleviate specific symptoms.
RESECTION OF RESIDUAL MASS AFTER SYSTEMIC THERAPY
Kim and Louie, in a 1992 report, were among the first to address the issue of whether patients would benefit from surgical resection of residual tumor after partial response to interleukin-2 therapy in patients with RCC (21) . Sixty-two of 399 patients (15.5 %) achieved an objective response after interleukin-2 immunotherapy. Eleven patients (all but one of whom had achieved a partial response) underwent resection of residual tumor in the lung, kidney, retroperitoneum, or pelvis. All 11 patients who had been rendered surgically free of disease after immunotherapy remained alive without clinical evidence of disease after a median follow-up of 21 months. In contrast, among patients who did not undergo surgery after immunotherapy, only 14 (78 %) of 18 patients who had had a complete response, and 15 (34 %) of 44 patients who had partial responses without surgery continued clinically free of disease.
Sherry and colleagues reported that 7 (44 %) of 16 patients with RCC who had undergone surgery after partial response (11 patients) or for disease progression after prior complete response (5 patients), had had no tumor progression 4 to 44 months after surgery (22) . Furthermore, 3 of 12 patients rendered disease-free by surgery remained disease-free after 2 years.
In 1993 Sella reported the experience with 17 patients who underwent surgical resection after prior interferon-α therapy for metastatic RCC at The University of Texas M. D. Anderson Cancer Center (23) . Despite finding viable cancer in the surgical specimen in 88 % of patients, 65 % of patients were disease-free at 12 months.
In 1998 Krishnamurthi reported on 14 patients with metastatic RCC who were treated at the Cleveland Clinic with initial biologic therapy followed by surgery to resect residual primary or metastatic RCC lesions (24) . Nine patients had an objective response to systemic therapy and five had stable disease. All patients were then rendered disease-free by surgical excision of residual or recurrent metastatic lesions and the primary tumor (if not previously resected). The cancer-specific survival rate at 3 years was 81.5 % and 7 patients were alive and disease-free after a mean follow-up of 41 months.
Our experience to date includes 81 patients who underwent resection of residual or stable disease after cytokine therapy (9). Forty-four patients underwent 52 resections of lung metastases after a median of 8 months of immunotherapy (range 2-19 months). The median time to recurrence in these patients was 9 months, and the median survival was 47 months (range 8-160 months). Eighteen patients underwent resection of locoregional recurrences after a median of 7 months of immunotherapy (range 3-11), nine of whom had recurrent disease (3 locally) a median of 14 months (11-32 months) after resection. Median survival was 23 months (6-68 months), with symptomatic patients having a worse prognosis. Twenty patients with lung metastases and 11 patients with local recurrence also received postoperative immunotherapy for 4 months. Patients who received postoperative immunotherapy had a trend toward improved survival of approximately 5 months compared with those not receiving immunotherapy after resection, although this difference was not statistically significant. The remaining 19 of the 81 surgery patients underwent resections of supradiaphragmatic lymph nodes (5), spine (5), brain (3), liver (2), pancreas (2), and appendicular bone (2) with a median survival of 15 months (range 1-62 months) for all presentations.
Patient G. P. L. illustrates the remarkable clinical course that is possible in some patients with metastatic RCC who undergo aggressive surgical resection of disease in combination with biological therapy. In October 1980, at age 43, he presented with a right renal mass and two pulmonary nodules. He underwent arterial embolization of the right kidney followed by radical nephrectomy and was started on medroxyprogesterone acetate. The pulmonary nodules remained stable until August 1987 when they were excised because of growth. A second wedge resection of the lung was performed in September 1989. In December 1990, he presented with jaundice, and a CT scan showed a liver metastasis plus several lesions in the pancreas. The patient was treated with interferon-α and floxuridine. His serum bi-lirubin level returned to normal, and the masses regressed more than 50 %. In January 1992, resection of 95 % of the pancreas, wedge resection of the liver, and resection of the gallbladder and the 1st and 2nd portions of the duodenum revealed 8 metastatic RCC nodules up to 3.8 cm in diameter; all soft tissue margins were negative for tumor. The patient did not receive additional biologic therapy postoperatively and did well until late 1999 when he was noted to have a palpable nodule in his parotid gland. A left parotidectomy performed in February 2000 revealed 2 RCC metastases. His disease did recur with multiple bony metastases in November 2000, and he was found to have a soft-tissue lesion in his iliopsoas muscle and new liver metastasis, for which he received three courses of gemcitabine, 5-fluorouracil, and interferon-α . He subsequently required a right parotidectomy in January 2002, excision of a gastric metastasis in May 2003, and multiple other orthopedic procedures, but he is currently alive with good performance status despite slowly progressive disease more than 23 years after presenting with metastatic RCC.
LOCAL RECURRENCE
Local recurrence in or near the renal fossa is a unique variant of advanced RCC that may, in fact, not truly represent metastatic disease. It may result from incomplete resection of the primary tumor or persistence of tumor in the regional lymph nodes, but it is generally associated with a poor prognosis, and surgical resection is usually considered, at least. Renal fossa recurrences may not produce symptoms until adjacent structures are invaded, particularly the posterior abdominal wall, which contributes to its seeming to be unresectable. Thus, only a few programs have taken an aggressive surgical approach toward the resection of local recurrences.
Tanguay reported our experience in which we resected 16 renal fossa recurrences; eight of these patients received preoperative immunotherapy (25) . Complete resection was possible in 15 patients, 12 of whom also had negative surgical margins. Twelve of 16 patients were alive after a median followup of 23.5 months. Of those 8 patients who did not receive initial immunotherapy, two have no clinical evidence of disease compared to 4 of 8 who did receive preoperative systemic therapy. These reports suggest that resection of a solitary local recurrence in a patient with no other sites of metastases, especially if a negative margin can be obtained, can be associated with long-term survival.
The value of preoperative systemic therapy has not been determined, but it should be considered, particularly in the patient with a large, less well-delineated mass. An MRI is potentially valuable to help define the limits of tumor, and the surgeon should plan for the possibility that the tumor is more extensive than expected. The greatest benefit of surgery seems to accrue to patients whose recurrence can be completely resected.
PALLIATION
Surgery may palliate local symptoms in selected patients. Nephrectomy is sometimes considered for intractable pain, hematuria, or relief of paraneoplastic syndromes, but usually the primary tumor can be controlled by embolization instead of surgery. Soft tissue metastases may bleed, cause pain or neurological problems, and resection can control these symptoms. Orthopedic procedures are particularly helpful in the palliation of pain and disability secondary to metastatic RCC. Open reduction and internal fixation for pathological fractures is obvious and standard. In some cases simple amputation may provide significant relief. Also, resection of a metastasis with insertion of prosthesis can provide dramatic relief of pain and restore function to a useless limb. Although the procedure has no impact on the overall disease course, it fully palliates the crippling effects of the metastasis and the patient is always very grateful. Palliative surgery should be considered when the potential benefits outweigh the morbidity of the surgery. It remains to be seen whether minimally invasive surgery like laparoscopy, and non-surgical ablative techniques like cryosurgery and radiofrequency ablation (RFA) will increase the opportunities for palliative surgery, but it does seem likely.
SUMMARY
The role of surgery for RCC in the era of emerging effective systemic therapy (usually immunotherapy)
is not yet defined except for solitary metastasis. The retrospective analysis of patients subjected to aggressive surgical management after systemic therapy reinforces the need to find better therapeutic modalities in order to achieve complete eradication of metastatic disease. In the meantime, however, we propose these guidelines. First, we would encourage aggressive surgical resection of the clinically solitary metastasis, whether synchronous or metachronous. Continue to follow those patients indefinitely, because relapse is quite likely, but do not give adjuvant systemic therapy unless on protocol. Second, limited metastases in only one organ may behave similarly to a solitary metastasis, and if the metastases are in a site amenable to surgical resection, e.g., lung, initial surgery might be reasonable. Systemic therapy for these patients is highly recommended and need not necessarily wait for recurrence. Third, for patients with multiple metastases, initial systemic therapy followed then by resection of any residual disease in selected patients seems to be supported by the experience at several medical centers. Apparently prolonged survival times have been observed after systemic therapy followed by surgery in highly selected patients, despite finding viable cancer in the overwhelming majority of specimens. One must be mindful of the morbidity of an attempt to remove all known disease, however, and try to weigh this against potential benefit. Only a prospective, randomized trial could ever confirm the value of an aggressive surgical approach to metastatic RCC. In the meantime, however, metastasectomy offers, at the very least, the opportunity to confirm the histologic response to systemic therapy, render some patients disease-free, and possibly promote long-term survival in selected patients.
